The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Camille C. B. Kockerols; Inge Geelen; Mark-David Levin; Jeroen J. W. M. Janssen; Avinash G. Dinmohamed; Mels Hoogendoorn; Jan J. Cornelissen; Peter E. Westerweel

doi:10.3324/haematol.2021.280501

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Camille C. B. Kockerols^*
, Inge Geelen
, Mark-David Levin
, Jeroen J. W. M. Janssen
, Avinash G. Dinmohamed
, Mels Hoogendoorn
, Jan J. Cornelissen
, Peter E. Westerweel

^*Corresponding author for this work

Albert Schweitzer Ziekenhuis
Erasmus MC
Amsterdam UMC - University of Amsterdam
Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht Netherlands
Medical Centre Leeuwarden
Albert Schweitzer Hospital, Dordrecht.
Erasmus University Rotterdam
Amsterdam University Medical Centers
Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

11 Downloads (Pure)

Original language	English
Pages (from-to)	1940-1943
Number of pages	4
Journal	Haematologica
Volume	107
Issue number	8
DOIs	https://doi.org/10.3324/haematol.2021.280501
Publication status	Published - 1 Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3324/haematol.2021.280501

The-use-of-hydroxyurea-pretreatment-in-chronic-myeloid-leukemia-in-the-current-tyrosine-kinase-inhib.pdfFinal published version, 343 KB

Cite this

@article{87d1a391b8fa4eee8aa7302c659a67c6,

title = "The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era",

author = "Kockerols, \{Camille C. B.\} and Inge Geelen and Mark-David Levin and Janssen, \{Jeroen J. W. M.\} and Dinmohamed, \{Avinash G.\} and Mels Hoogendoorn and Cornelissen, \{Jan J.\} and Westerweel, \{Peter E.\}",

note = "Funding Information: The Pharos-CML database was financially supported by grants from Novartis and BMS to the Netherlands Comprehensive Cancer Organisation (IKNL). The authors have no other conflicts of interest to disclose.",

year = "2022",

month = aug,

day = "1",

doi = "10.3324/haematol.2021.280501",

language = "English",

volume = "107",

pages = "1940--1943",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "8",

}

TY - JOUR

T1 - The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

AU - Kockerols, Camille C. B.

AU - Geelen, Inge

AU - Levin, Mark-David

AU - Janssen, Jeroen J. W. M.

AU - Dinmohamed, Avinash G.

AU - Hoogendoorn, Mels

AU - Cornelissen, Jan J.

AU - Westerweel, Peter E.

N1 - Funding Information: The Pharos-CML database was financially supported by grants from Novartis and BMS to the Netherlands Comprehensive Cancer Organisation (IKNL). The authors have no other conflicts of interest to disclose.

PY - 2022/8/1

Y1 - 2022/8/1

UR - https://www.scopus.com/pages/publications/85135421360

UR - https://www.ncbi.nlm.nih.gov/pubmed/35354254

UR - https://www.scopus.com/pages/publications/85135421360

U2 - 10.3324/haematol.2021.280501

DO - 10.3324/haematol.2021.280501

M3 - Comment/Letter to the editor

C2 - 35354254

SN - 0390-6078

VL - 107

SP - 1940

EP - 1943

JO - Haematologica

JF - Haematologica

IS - 8

ER -

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

UN SDGs

Access to Document

Other files and links

Cite this